Anuncia Medical, Inc. Honored with an AZBio Fast Lane Award

Relieving Pressure on the Brain

Cerebrospinal fluid (CSF) normally flows through the cavities (ventricles) of our brains and bathes our brain and spinal column. Hydrocephalus is a condition caused by a buildup of this fluid deep within the brain. The excess fluid puts pressure on the brain. This pressure can damage brain tissues and cause a range of brain function problems. Hydrocephalus can happen at any age, but it occurs more frequently among infants and adults 60 and over.Continue reading

Phoenix Mayor Kate Gallego honored with AZBio Public Service Award

The path for a cure for cancer will run through Phoenix.

Sit down with Phoenix Mayor Kate Gallego and bring up the subject of biosciences, you will experience a burst of energy and insight about the innovation in healthcare taking place across Phoenix, including the growth of businesses creating jobs, and a personal passion that, “the path for a cure for cancer will run through Phoenix.”Continue reading

Saving money for Medicare by abandoning new drugs for Medicare patients

By Steve Potts, PhD

The new Inflation Reduction Act was written in part to improve access to prescription drugs. But just like many potent drugs, the law too has side effects. As a small biotech drug developer, here’s the most toxic: It’s forcing me to choose to develop a drug for kids instead of a drug for their grandparents, when I could be developing both.Continue reading

Dr. Roberta Diaz Brinton is the Arizona Bioscience Researcher of the Year

Roberta Diaz Brinton, PhD is an internationally recognized expert in the cause and treatment of Alzheimer’s disease.  Her findings have re-shaped how the field understands the disease and unlocked the potential for new and innovative therapies to prevent and treat Alzheimer’s. Dr. Brinton will be honored by Arizona’s life science and healthcare community at the AZBio Awards on September 28, 2022 at the Phoenix Convention Center. Continue reading

Aqualung Therapeutics Receives the AZBio Fast Lane Award and Achieves Key FDA-Related Milestones

Aqualung Therapeutics, an immunotherapeutics biotech company with an anti-inflammatory therapeutic platform for serious unchecked inflammatory disorders, announced the achievement of two key FDA milestones for their therapeutic mAb ALT-100. First is the successful FDA IND submission for the indication of Acute Respiratory Distress Syndrome (ARDS). Second is the scheduling of an FDA Pre-IND type B meeting (September 14th) to discuss the targeted use of ALT-100 mAb in Radiation-induced Lung Injury and Fibrosis.Continue reading